4,775 Shares in Natera, Inc. $NTRA Bought by Sax Wealth Advisors LLC

Key Points

• Sax Wealth Advisors acquired 4,775 Natera shares worth approximately $1.97 million, while institutional investors collectively own 99.90% of the company.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year, and posted an adjusted loss of $0.47 per share, narrowly beating analyst expectations.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and several firms raising price targets to as high as $480; however, insiders sold $16.1 million of stock over the past 90 days.

Sax Wealth Advisors LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,775 shares of the medical research company's stock, valued at approximately $1,974,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Natera during the second quarter worth $2,962,770,000. Castle Hook Partners LP boosted its position in shares of Natera by 24.1% during the fourth quarter. Castle Hook Partners LP now owns 2,167,869 shares of the medical research company's stock worth $496,637,000 after buying an additional 420,621 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Natera by 1.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company's stock worth $238,334,000 after buying an additional 11,793 shares during the period. Maverick Capital Ltd. grew its stake in shares of Natera by 24.1% in the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company's stock valued at $234,315,000 after buying an additional 227,605 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Natera by 10.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company's stock valued at $226,220,000 after buying an additional 80,440 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Trading Down 0.5%

Natera stock opened at $395.65 on Wednesday. Natera, Inc. has a 52-week low of $170.82 and a 52-week high of $437.41. The company's 50 day moving average is $351.59 and its two-hundred day moving average is $271.46.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.74) EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Citigroup boosted their price objective on Natera from $365.00 to $480.00 and gave the company a "buy" rating in a report on Tuesday, October 6th. Royal Bank Of Canada increased their target price on Natera from $350.00 to $460.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. UBS Group raised their target price on Natera from $290.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. Sanford C. Bernstein initiated coverage on Natera in a research report on Friday, June 26th. They issued an "outperform" rating and a $310.00 target price for the company. Finally, Barclays lifted their target price on Natera from $340.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and a consensus target price of $363.93.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $414.22, for a total value of $1,242,660.00. Following the sale, the insider directly owned 106,914 shares in the company, valued at approximately $44,285,917.08. This trade represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Fesko sold 6,517 shares of Natera stock in a transaction on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider owned 197,257 shares of the company's stock, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 52,985 shares of company stock worth $16,119,137 over the last ninety days. Insiders own 5.05% of the company's stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.